Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
9.26
-0.24 (-2.53%)
At close: Apr 28, 2026, 4:00 PM EDT
9.15
-0.11 (-1.19%)
After-hours: Apr 28, 2026, 7:52 PM EDT
Climb Bio Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Climb Bio stock have an average target of 16.82, with a low estimate of 8.00 and a high estimate of 26. The average target predicts an increase of 81.64% from the current stock price of 9.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Climb Bio stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 6 | 6 |
| Buy | 3 | 3 | 3 | 4 | 5 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $18 | Buy | Maintains | $10 → $18 | +94.38% | Apr 21, 2026 |
| Mizuho | Mizuho | Buy Initiates $18 | Buy | Initiates | $18 | +94.38% | Apr 15, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | -13.61% | Apr 8, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +180.78% | Mar 24, 2026 |
| Truist Securities | Truist Securities | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +83.59% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.10
from -0.90
EPS Next Year
-1.28
from -1.10
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.98 | -1.17 | ||||||
| Avg | -1.10 | -1.28 | ||||||
| Low | -1.18 | -1.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.